A challenging economic environment is constricting biotech deal flow. But for well-capitalized Lantheus, these tough times ...

Lantheus' pipeline-building drive in radiopharma ... which was extended last year with the acquisition of NTI-1309, a PET oncology imaging agent that targets cancer biomarker fibroblast activation ...

MK-6420. Lantheus is also attempting to expand its radiopharmaceutical diagnostic offerings, the most notable of which is MK-6420, a second-generation F18-labeled PET imaging agent that targets ...

Through the transaction, Lantheus has acquired OCTEVY, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, which complements Lantheus’ therapeutic candidate ...

"We are excited to be partnering with Lantheus to bring Granzyme B PET imaging to the forefront. This strategic collaboration creates a clear path to commercialization with an ideal partner in the ...

Riley lowered the firm’s price target on Lantheus (LNTH ... Gozellix received FDA approval for the next-generation PSMA-PET imaging agent for prostate cancer, and the firm will closely watch ...